{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T10:27:30Z","timestamp":1695032850778},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s40119-016-0061-7","type":"journal-article","created":{"date-parts":[[2016,4,22]],"date-time":"2016-04-22T10:10:09Z","timestamp":1461319809000},"page":"85-100","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and Safety of Novel Oral Anticoagulants for Atrial Fibrillation Ablation: An Updated Meta-Analysis"],"prefix":"10.1007","volume":"5","author":[{"given":"Ajay","family":"Vallakati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Madmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhu","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun","family":"Kanmanthareddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sampath","family":"Gunda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhanunjaya","family":"Lakkireddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,22]]},"reference":[{"key":"61_CR1","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","volume":"98","author":"EJ Benjamin","year":"1998","unstructured":"Benjamin EJ, Wolf PA, D\u2019Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946\u201352.","journal-title":"Circulation"},{"key":"61_CR2","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","volume":"285","author":"AS Go","year":"2001","unstructured":"Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA J Am Med Assoc. 2001;285:2370\u20135.","journal-title":"JAMA J Am Med Assoc"},{"key":"61_CR3","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0735-1097(00)01107-4","volume":"37","author":"SS Chugh","year":"2001","unstructured":"Chugh SS, Blackshear JL, Shen WK, Hammill SC, Gersh BJ. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol. 2001;37:371\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"61_CR4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.7326\/0003-4819-151-5-200909010-00003","volume":"151","author":"DE Singer","year":"2009","unstructured":"Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151:297\u2013305.","journal-title":"Ann Intern Med"},{"key":"61_CR5","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139\u201351.","journal-title":"N Engl J Med"},{"key":"61_CR6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u201391.","journal-title":"N Engl J Med"},{"key":"61_CR7","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981\u201392.","journal-title":"N Engl J Med"},{"key":"61_CR8","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093\u2013104.","journal-title":"N Engl J Med"},{"key":"61_CR9","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1161\/CIR.0b013e318290826d","volume":"127","author":"LS Wann","year":"2013","unstructured":"Wann LS, Curtis AB, Ellenbogen KA, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF\/AHA\/ESC and 2011 ACCF\/AHA\/HRS recommendations): a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines. Circulation. 2013;127:1916\u201326.","journal-title":"Circulation"},{"key":"61_CR10","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1161\/CIRCOUTCOMES.112.967299","volume":"5","author":"K Kirley","year":"2012","unstructured":"Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes. 2012;5:615\u201321.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"61_CR11","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.amjcard.2013.12.027","volume":"113","author":"P Sardar","year":"2014","unstructured":"Sardar P, Nairooz R, Chatterjee S, Wetterslev J, Ghosh J, Aronow WS. Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation. Am J Cardiol. 2014;113:1173\u20137.","journal-title":"Am J Cardiol"},{"key":"61_CR12","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.cjca.2013.07.005","volume":"29","author":"M Shurrab","year":"2013","unstructured":"Shurrab M, Morillo CA, Schulman S, et al. Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis. Can J Cardiol. 2013;29:1203\u201310.","journal-title":"Can J Cardiol"},{"key":"61_CR13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10840-013-9813-7","volume":"37","author":"BA Steinberg","year":"2013","unstructured":"Steinberg BA, Hasselblad V, Atwater BD, et al. Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies. J Interv Cardiac Electrophysiol Int J Arrhythm Pacing. 2013;37:213\u201321.","journal-title":"J Interv Cardiac Electrophysiol Int J Arrhythm Pacing"},{"key":"61_CR14","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA J Am Med Assoc. 2000;283:2008\u201312.","journal-title":"JAMA J Am Med Assoc"},{"key":"61_CR15","first-page":"S74","volume":"10","author":"A Arshad","year":"2013","unstructured":"Arshad A, Buch E, Hamam I, et al. Comparative safety of anticoagulation strategies peri-ablation for atrial fibrillation: data from a large multicenter study. Heart Rhythm. 2013;10:S74.","journal-title":"Heart Rhythm"},{"key":"61_CR16","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1161\/CIRCEP.113.000320","volume":"6","author":"M Bassiouny","year":"2013","unstructured":"Bassiouny M, Saliba W, Rickard J, et al. Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol. 2013;6:460\u20134.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"61_CR17","doi-asserted-by":"crossref","first-page":"E276","DOI":"10.1016\/S0735-1097(13)60276-4","volume":"61","author":"M Bernard","year":"2013","unstructured":"Bernard M, Brabham W, Netzler P, et al. Comparison of atrial fibrillation ablation bleeding and thrombotic complications with dabigatran, rivaroxaban and warfarin. J Am Coll Cardiol. 2013;61:E276.","journal-title":"J Am Coll Cardiol"},{"key":"61_CR18","first-page":"S421","volume":"9","author":"CR Ellis","year":"2012","unstructured":"Ellis CR, Streur MM, Nagarakanti R. Safety and efficacy of dabigatran versus warfarin in patients undergoing left atrial catheter ablation. Heart Rhythm. 2012;9:S421.","journal-title":"Heart Rhythm"},{"key":"61_CR19","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1016\/j.hrthm.2012.02.021","volume":"10","author":"VK Gadiyaram","year":"2013","unstructured":"Gadiyaram VK, Boero I, Kawata H, et al. Rivaroxaban has similar safety and efficacy as warfarin for peri-procedural anticoagulation for atrial fibrillation ablation. Heart Rhythm. 2013;10:S142\u20133.","journal-title":"Heart Rhythm"},{"key":"61_CR20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10840-013-9800-z","volume":"37","author":"DE Haines","year":"2013","unstructured":"Haines DE, Mead-Salley M, Salazar M, et al. Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation. J Interv Cardiac Electrophysiol. 2013;37:233\u20139.","journal-title":"J Interv Cardiac Electrophysiol"},{"key":"61_CR21","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/pace.12195","volume":"36","author":"H Ichiki","year":"2013","unstructured":"Ichiki H, Oketani N, Ishida S, et al. The incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation: comparison of warfarin and dabigatran. PACE Pacing Clin Electrophysiol. 2013;36:1328\u201335.","journal-title":"PACE Pacing Clin Electrophysiol"},{"key":"61_CR22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10840-013-9801-y","volume":"37","author":"K Imamura","year":"2013","unstructured":"Imamura K, Yoshida A, Takei A, et al. Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay. J Interv Cardiac Electrophysiol. 2013;37:223\u201331.","journal-title":"J Interv Cardiac Electrophysiol"},{"key":"61_CR23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10840-013-9793-7","volume":"37","author":"DW Kaiser","year":"2013","unstructured":"Kaiser DW, Streur MM, Nagarakanti R, Whalen SP, Ellis CR. Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter. J Interv Cardiac Electrophysiol. 2013;37:241\u20137.","journal-title":"J Interv Cardiac Electrophysiol"},{"key":"61_CR24","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1253\/circj.CJ-12-0498","volume":"76","author":"K Kaseno","year":"2012","unstructured":"Kaseno K, Naito S, Nakamura K, et al. Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. Circ J. 2012;76:2337\u201342.","journal-title":"Circ J"},{"key":"61_CR25","doi-asserted-by":"crossref","first-page":"E401","DOI":"10.1016\/S0735-1097(13)60401-5","volume":"61","author":"S Khan","year":"2013","unstructured":"Khan S, Duggal M, Dunskis P, Bhan A. Periprocedural dabigatran in patients undergoing catheter ablation for at rial fibrillation. J Am Coll Cardiol. 2013;61:E401.","journal-title":"J Am Coll Cardiol"},{"key":"61_CR26","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.hrthm.2012.12.011","volume":"10","author":"JS Kim","year":"2013","unstructured":"Kim JS, She F, Jongnarangsin K, et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm. 2013;10:483\u20139.","journal-title":"Heart Rhythm"},{"key":"61_CR27","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jacc.2013.11.039","volume":"63","author":"D Lakkireddy","year":"2014","unstructured":"Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2014;63:982\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"61_CR28","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/jce.12143","volume":"24","author":"W Maddox","year":"2013","unstructured":"Maddox W, Kay GN, Yamada T, et al. Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2013;24:861\u20135.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"61_CR29","first-page":"S270","volume":"9","author":"I Mendoza","year":"2012","unstructured":"Mendoza I, Helguera M, Baez-Escudero J, Reina J, Pinski SL. Atrial fibrillation ablation on uninterrupted anticoagulation with dabigatran versus warfarin. Heart Rhythm. 2012;9:S270\u20131.","journal-title":"Heart Rhythm"},{"key":"61_CR30","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1016\/j.cjca.2013.07.293","volume":"29","author":"K Mohajer","year":"2013","unstructured":"Mohajer K, Haley C, Simpson C, et al. Comparison of dabigatran and conventional anticoagulation practices in patients undergoing elective left atrial ablation. Can J Cardiol. 2013;29:S184.","journal-title":"Can J Cardiol"},{"key":"61_CR31","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/pace.12036","volume":"36","author":"T Nin","year":"2013","unstructured":"Nin T, Sairaku A, Yoshida Y, et al. A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. PACE Pacing Clin Electrophysiol. 2013;36:172\u20139.","journal-title":"PACE Pacing Clin Electrophysiol"},{"key":"61_CR32","first-page":"S456","volume":"11","author":"D Snipelisky","year":"2014","unstructured":"Snipelisky D, Ray J, Ung R, Duart M, Kauffman C, Kusumoto F. A comparison of bleeding complications between warfarin and dabigatran in patients undergoing cryoablation. Heart Rhythm. 2014;11:S456\u20137.","journal-title":"Heart Rhythm"},{"key":"61_CR33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10840-014-9888-9","volume":"40","author":"G Stepanyan","year":"2014","unstructured":"Stepanyan G, Badhwar N, Lee RJ, et al. Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation. J Interv Cardiac Electrophysiol. 2014;40:33\u20138.","journal-title":"J Interv Cardiac Electrophysiol"},{"key":"61_CR34","first-page":"S228","volume":"11","author":"S Tao","year":"2014","unstructured":"Tao S, Kenichiro O, Yuichi O, et al. Efficacy and safety of rivaroxaban versus warfarin as uninterrupted anticoagulation for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm. 2014;11:S228.","journal-title":"Heart Rhythm"},{"key":"61_CR35","first-page":"S395","volume":"11","author":"A Ueno","year":"2014","unstructured":"Ueno A, Morita N, Iida T, Fujibayashi D, Kobayashi Y. Evaluation of peri-procedural coagulation status of atrial fibrillation ablation; impact of different anticoagulants on the risk of silent cerebral infarction. Heart Rhythm. 2014;11:S395.","journal-title":"Heart Rhythm"},{"key":"61_CR36","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40261-013-0081-1","volume":"33","author":"H Yamaji","year":"2013","unstructured":"Yamaji H, Murakami T, Hina K, et al. Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation. Clin Drug Investig. 2013;33:409\u201318.","journal-title":"Clin Drug Investig"},{"key":"61_CR37","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10840-012-9719-9","volume":"35","author":"SV Konduru","year":"2012","unstructured":"Konduru SV, Cheema AA, Jones P, Li Y, Ramza B, Wimmer AP. Differences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarin. J Interv Cardiac Electrophysiol. 2012;35:277\u201384.","journal-title":"J Interv Cardiac Electrophysiol"},{"key":"61_CR38","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.jacc.2011.12.014","volume":"59","author":"D Lakkireddy","year":"2012","unstructured":"Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2012;59:1168\u201374.","journal-title":"J Am Coll Cardiol"},{"key":"61_CR39","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/eurheartj\/ehr257","volume":"33","author":"H Pavaci","year":"2012","unstructured":"Pavaci H, Reents T, Ammar S, et al. Safety and efficacy of dabigatran in patients undergoing left atrial ablation procedures: a case matched analysis. Eur Heart J. 2012;33:60\u20131.","journal-title":"Eur Heart J"},{"key":"61_CR40","first-page":"S201","volume":"9","author":"CP Rowley","year":"2012","unstructured":"Rowley CP, Bradford NS, Bernard ML, et al. Complications of atrial fibrillation ablation in patients anticoagulated with dabigatran compared to warfarin. Heart Rhythm. 2012;9:S201.","journal-title":"Heart Rhythm"},{"key":"61_CR41","first-page":"S203","volume":"9","author":"D Snipelisky","year":"2012","unstructured":"Snipelisky D, Kauffman C, Kusumoto F. A comparison of bleeding complications post ablation between warfarin and dabigatran. Heart Rhythm. 2012;9:S203.","journal-title":"Heart Rhythm"},{"key":"61_CR42","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jacc.2013.02.025","volume":"61","author":"JP Piccini","year":"2013","unstructured":"Piccini JP, Stevens SR, Lokhnygina Y, et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF Trial. J Am Coll Cardiol. 2013;61:1998\u20132006.","journal-title":"J Am Coll Cardiol"},{"key":"61_CR43","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jacc.2013.02.001","volume":"61","author":"JL Anderson","year":"2013","unstructured":"Anderson JL, Halperin JL, Albert NM, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF\/AHA\/ESC and 2011 ACCF\/AHA\/HRS recommendations): a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61:1935\u201344.","journal-title":"J Am Coll Cardiol"},{"key":"61_CR44","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1093\/europace\/eut239","volume":"15","author":"AA Bin Abdulhak","year":"2013","unstructured":"Bin Abdulhak AA, Khan AR, Tleyjeh IM, et al. Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Europace Eur Pacing Arrhythm Cardiac Electrophysiol J Work Groups Cardiac Pacing Arrhythm Cardiac Cell Electrophysiol Eur Soc Cardiol. 2013;15:1412\u201320.","journal-title":"Europace Eur Pacing Arrhythm Cardiac Electrophysiol J Work Groups Cardiac Pacing Arrhythm Cardiac Cell Electrophysiol Eur Soc Cardiol"},{"key":"61_CR45","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1161\/CIRCULATIONAHA.110.937953","volume":"122","author":"F Gaita","year":"2010","unstructured":"Gaita F, Caponi D, Pianelli M, et al. Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation. Circulation. 2010;122:1667\u201373.","journal-title":"Circulation"},{"key":"61_CR46","first-page":"S384","volume":"10","author":"A Ueno","year":"2013","unstructured":"Ueno A, Morita N, Iida T, Fujibayashi D, Kobayashi Y. Comparison of coagulation status using dabigatran with warfarin for periprocedural anticoagulation during atrial fibrillation ablation procedure. Heart Rhythm. 2013;10:S384.","journal-title":"Heart Rhythm"},{"key":"61_CR47","doi-asserted-by":"crossref","unstructured":"Fanning JP, Wesley AJ, Wong AA, Fraser JF. Emerging spectra of silent brain infarction. Stroke J Cereb Circ 2014;45:3461\u20133471.","DOI":"10.1161\/STROKEAHA.114.005919"},{"key":"61_CR48","first-page":"870","volume":"80","author":"K Nakamura","year":"2016","unstructured":"Nakamura K, Naito S, Sasaki T, et al. Silent cerebral ischemic lesions after catheter ablation of atrial fibrillation in patients on 5 types of periprocedural oral anticoagulation-predictors of diffusion-weighted imaging-positive lesions and follow-up magnetic resonance imaging. Circ J Off J Jpn Circ Soc. 2016;80:870\u20137.","journal-title":"Circ J Off J Jpn Circ Soc"},{"key":"61_CR49","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.hrthm.2015.02.028","volume":"12","author":"L Biase Di","year":"2015","unstructured":"Di Biase L, Lakkireddy D, Trivedi C, et al. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study. Heart Rhythm Off J Heart Rhythm Soc. 2015;12:1162\u20138.","journal-title":"Heart Rhythm Off J Heart Rhythm Soc"},{"key":"61_CR50","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/jce.12856","volume":"27","author":"A Rillig","year":"2016","unstructured":"Rillig A, Lin T, Plesman J, et al. Apixaban, rivaroxaban, and dabigatran in patients undergoing atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2016;27:147\u201353.","journal-title":"J Cardiovasc Electrophysiol"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-016-0061-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T11:33:11Z","timestamp":1498303991000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40119-016-0061-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,22]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["61"],"URL":"https:\/\/doi.org\/10.1007\/s40119-016-0061-7","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,22]]}}}